Abstract：
Breast cancer mainly affects women and is the second leading cause of cancer-related deaths worldwide. Breast cancer affects women aged 15-59. The current study explored periplocin\'s anticancer activities against breast cancer MDA-MB-231 cells by down-regulating the PI3K/Akt/mTOR pathway. The MTT assay assessed control-treated and periplocin (2.5-50 μM) treated MDA-MB-231 cell viability. ROS accumulation and apoptosis levels in periplocin-treated cells were examined using DAPI, dual staining, and Annexin V-FITC/PI assays. Caspase enzymes were studied using assay kits. Flow cytometry was used to measure cell cycle distributions. Periplocin-treated cells were analyzed using RT-PCR assays and insilico analyses for the expression of PI3K/Akt/mTOR molecules. The periplocin treatment remarkably reduced the viability of the MDA-MB-231 cells, with an IC50 concentration of 7.5 μM. The fluorescent staining assays revealed a substantial increase in ROS levels and apoptotic events in the periplocin-treated cells. The flow cytometry analysis revealed that periplocin triggered apoptosis and arrested the cell cycle in G0/G1 phases. Periplocin increased the caspase-3, -8, and -9 enzyme activities. In MDA-MB-231 cells, Periplocin decreased PI3K/Akt/mTOR activity, and in silico analysis, Periplocin was inhibited by CDK8-Cyclin C interactions. Periplocin has anticancer properties against breast cancer and may be an effective therapeutic agent for treating breast cancer.
摘要：
乳腺癌主要影响女性，是全球癌症相关死亡的第二大原因。乳腺癌影响15-59岁的女性。本研究通过下调PI3K/Akt/mTOR通路,探讨了perplocin对乳腺癌MDA-MB-231细胞的抗癌活性。MTT测定评估了对照处理的和periplocin(2.5-50μM)处理的MDA-MB-231细胞活力。ROS积累和细胞凋亡水平在包膜素处理的细胞使用DAPI检查，双重染色，和膜联蛋白V-FITC/PI测定。使用测定试剂盒研究半胱天冬酶。流式细胞术用于测量细胞周期分布。对于PI3K/Akt/mTOR分子的表达,使用RT-PCR测定和计算机分析来分析经周霉素处理的细胞。perplocin处理显著降低了MDA-MB-231细胞的活力,IC50浓度为7.5μM。荧光染色测定显示，在周聚霉素处理的细胞中，ROS水平和凋亡事件显着增加。流式细胞术分析显示，periplocin触发了细胞凋亡并将细胞周期阻滞在G0/G1期。Periplocin增加了caspase-3，-8和-9酶的活性。在MDA-MB-231细胞中，Periplocin降低PI3K/Akt/mTOR活性，和硅分析，Periplocin被CDK8-CyclinC相互作用抑制。Periplocin具有抗乳腺癌的抗癌特性，可能是治疗乳腺癌的有效治疗剂。
